Alana Hippensteele, Lead Editor

New data have resulted in updated guidelines for neoadjuvant cemiplimab.

There are currently no effective treatments for CIPN prevention.

These data support a paradigm shift in the treatment of locally advanced rectal cancer.

For many patients with C diff, the experience of medical gaslighting is a common one because many health care providers lack education and familiarity with the disease.

FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.

Neither of the 2 current standards of care offers patients a cure.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

A panel at the Advanced Topics for Oncology Pharmacy Professionals Summit discusses strategies to address patients’ fears and distrust of the medical and scientific community.

Effective implementation of the Inflation Reduction Act may allow legislators to shift their focus toward controversial pharmacy benefit manager practices, according to a panel discussion during the ATOPP Summit.

Because of its prevalence in approximately 50% of breast cancers, the outcomes of HER2-low treatment have a significant impact on patient outcomes.

Updated phase 3 trial data provide practice-changing findings.

The single institution study compared fixed dose capecitabine to standard dose capecitabine to compare efficacy and tolerability in metastatic breast cancer.

The benefit of ribociclib was seen as consistent against all of the stratification factors in the phase III study.

Heidi Finnes, PharmD, BCOP, FHOPA, addresses how the study data may impact the treatment of IDH1/2 mutating gliomas going forward.

Panelists discuss the potential impact of the study data presented at the ASCO 2023 Annual Meeting, which led to significant response from the field.

The ASCO abstracts were on the TALAPRO-2 trial (abstract 5053) and PROpel trial (abstract 5012).

For squamous cell carcinoma systemic therapy that is not concurrent with radiation therapy, preferred regimens are immune checkpoint inhibitors.

Depression can affect the trajectory of treatment and associated outcomes.

Providing this treatment for patients with cancer may be a smoother transition for oncology professionals than they might expect.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Current standard of care gives 2 poor options to patients, neither of which cure grade 2 gliomas.

Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.

Biliary tract cancers have become the model for precision oncology because of its complex molecular landscape.

FR alpha expression is limited on normal cells, but upregulated on cancers such as ovarian, endometrial, and triple-negative breast cancers.

Fecal microbiota transplant from responders to non-responders was able to rescue immune checkpoint inhibition use in patients with melanoma, with 40% of patients showing clinical benefit.

High tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades.

During a fireside chat, USP CEO Ronald T. Piervincenzi, PhD, and the Honorable Dr. Oh Yu-Kyoung, Minister of MFDS, Republic of Korea, discuss interruptions to the medical supply chain and the interventions used.

The impact that socioeconomic inequities can have on a child’s hippocampal volume may have implications for their success and experience pursuing educational endeavors.